- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.04. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 31.03. | Bicara Therapeutics To Rally Around 121%? Here Are 10 Top Analyst Forecasts For Tuesday | 1 | Benzinga.com | ||
| 31.03. | H.C. Wainwright raises Bicara Therapeutics stock price target on trial progress | 3 | Investing.com | ||
| 31.03. | H.C. Wainwright hebt Kursziel für Bicara Therapeutics nach Studienfortschritten an | 2 | Investing.com Deutsch | ||
| 31.03. | Citizens reiterates Bicara Therapeutics stock rating on trial progress | 1 | Investing.com | ||
| 30.03. | Bicara Therapeutics Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 30.03. | Bicara-Aktie steigt nach FDA-Sonderstatus und überzeugenden Studiendaten zu Krebsmedikament | 4 | Investing.com Deutsch | ||
| BICARA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 30.03. | Bicara Therapeutics GAAP EPS of -$0.68 | 1 | Seeking Alpha | ||
| 30.03. | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | 129 | GlobeNewswire (Europe) | Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent loading... ► Artikel lesen | |
| 30.03. | Bicara Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.03. | Bicara Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call | 1 | Benzinga.com | ||
| 25.03. | BofA-Studie treibt Aktie von Bicara Therapeutics an | 2 | Investing.com Deutsch | ||
| 23.03. | Bicara Therapeutics Inc.: Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET | 1 | GlobeNewswire (USA) | ||
| 04.03. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | 4 | GlobeNewswire (USA) | ||
| 26.02. | Bicara Therapeutics closes $172.5 million stock offering | 1 | Investing.com | ||
| 26.02. | Bicara Therapeutics schließt Aktienplatzierung über 172,5 Millionen US-Dollar ab | 3 | Investing.com Deutsch | ||
| 26.02. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | 1 | GlobeNewswire (USA) | ||
| 25.02. | Bicara Therapeutics prices $150 million stock offering at $16 | 2 | Investing.com | ||
| 25.02. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 24.02. | Bicara Therapeutics kündigt Aktienemission im Wert von 150 Millionen US-Dollar an | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNOVANT | 26,645 | +0,36 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,900 | +5,04 % | Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst | ||
| NURIX THERAPEUTICS | 16,890 | +3,62 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 14,530 | +1,25 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones | Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended... ► Artikel lesen | |
| TREVI THERAPEUTICS | 13,990 | +4,87 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 9,490 | -5,57 % | 4D Molecular Therapeutics, Inc.: 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones | Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data... ► Artikel lesen | |
| ERASCA | 18,940 | +6,23 % | Jefferies reiterates Erasca stock Buy rating on rival trial data | ||
| ZENAS BIOPHARMA | 21,340 | 0,00 % | Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) | - Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare - - Obexelimab also met and demonstrated statistically... ► Artikel lesen | |
| TYRA BIOSCIENCES | 36,140 | +2,55 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| TANGO THERAPEUTICS | 24,230 | +0,66 % | Leerink raises Tango Therapeutics stock price target on PDAC data | ||
| ADMA BIOLOGICS | 10,630 | +1,33 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,450 | -0,08 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| EVOTEC | 5,540 | +2,78 % | EQS-News: Evotec SE: Evotec gibt Ergebnisse für das vierte Quartal und Gesamtjahr 2025 bekannt: Grundlage für profitables Wachstum | EQS-News: Evotec SE
/ Schlagwort(e): Jahresergebnis
Evotec gibt Ergebnisse für das vierte Quartal und Gesamtjahr 2025 bekannt: Grundlage für profitables Wachstum
08.04.2026... ► Artikel lesen | |
| MAZE THERAPEUTICS | 27,600 | -0,29 % | Zifo Technologies: Zifo and Maze Therapeutics Partner to Power Precision Medicine | SAN FRANCISCO, Feb. 18, 2026 /PRNewswire/ -- Zifo, the leading global enabler of AI and data-driven enterprise informatics for science driven organizations and Maze Therapeutics Inc have... ► Artikel lesen | |
| ARCELLX | 114,89 | +0,01 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen |
Das Unternehmen BICARA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,35 % bei einem Aktienkurs von 23,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BICARA THERAPEUTICS INC finden Sie auf Wallstreet Online.